138,485 Shares in Accuray Incorporated (NASDAQ:ARAY) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in shares of Accuray Incorporated (NASDAQ:ARAY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 138,485 shares of the medical equipment provider’s stock, valued at approximately $249,000. XTX Topco Ltd owned 0.14% of Accuray at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Foundry Partners LLC grew its holdings in shares of Accuray by 51.3% during the 3rd quarter. Foundry Partners LLC now owns 2,187,160 shares of the medical equipment provider’s stock worth $3,937,000 after purchasing an additional 741,900 shares in the last quarter. Armistice Capital LLC acquired a new stake in Accuray during the second quarter valued at approximately $910,000. Los Angeles Capital Management LLC bought a new stake in shares of Accuray in the 3rd quarter valued at approximately $418,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Accuray by 489.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 277,859 shares of the medical equipment provider’s stock worth $500,000 after buying an additional 230,695 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. lifted its position in shares of Accuray by 143.1% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 384,944 shares of the medical equipment provider’s stock worth $693,000 after buying an additional 226,602 shares during the period. Institutional investors and hedge funds own 64.08% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com cut Accuray from a “buy” rating to a “hold” rating in a research report on Friday, November 15th.

Accuray Price Performance

Shares of Accuray stock opened at $1.79 on Thursday. Accuray Incorporated has a 1-year low of $1.40 and a 1-year high of $3.05. The firm’s 50-day moving average price is $1.91 and its two-hundred day moving average price is $1.88. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. The stock has a market capitalization of $180.01 million, a price-to-earnings ratio of -10.53 and a beta of 1.44.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.04). The firm had revenue of $101.55 million during the quarter, compared to analysts’ expectations of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same period last year, the firm posted ($0.03) EPS. On average, equities analysts predict that Accuray Incorporated will post 0.01 earnings per share for the current fiscal year.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.